Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two versus six weeks of intravenous antibiotics for acute prosthetic hip or knee joint infection treated with DAIR
ACTRN12617000127303Phase 4Completed
- Sponsor
- John Hunter Hospital
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of rifampicin, fusidic acid, ciprofloxacin and doxycycline in periprosthetic joint infection (PJI) (2 arms), sponsored by John Hunter Hospital. Primary endpoint: Seven-level ordinal outcome at 12 months. Started May 2017; status: completed.
02
Drugs
rifampicinfusidic acidciprofloxacindoxycycline
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on ACTRN12617000127303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000127303.